Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …

Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly
supplanting long-established traditional cell lines as preferred models for conducting basic and …

Introduction Identification of new therapeutic agents for breast cancer (BC) requires preclinical
models that reproduce the molecular characteristics of their respective clinical tumors. In …

Breast cancers (BCs) typically express estrogen receptors (ERs) but frequently exhibit de
novo or acquired resistance to hormonal therapies. Here, we show that short-term treatment …

Background and Purpose In recent years, the treatment landscape for breast cancer has
undergone significant advancements, with the introduction of several new anticancer agents. …

Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient
mice suitable for pharmacologic preclinical assays. Experimental Design: 200 samples of …

The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured
in pre-clinical models. We have created a large collection of breast cancer patient-derived …

Modulation of chromatin structure via histone modification is a major epigenetic mechanism
and regulator of gene expression. However, the contribution of chromatin features to tumor …

The persistence of cancer cells resistant to therapy remains a major clinical challenge. In
triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence risk …

Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes
and responses to therapy. To discover potential therapeutic targets for the poor prognosis-…